Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Osimert 80 mg
Osimertinib 80 mg tablets – Everest Pharmaceuticals Ltd.
Approved for adults with EGFR-mutated non-small cell lung cancer (NSCLC) — first-line metastatic, adjuvant after resection, or after prior EGFR therapy with T790M mutation.
- Clinical outcomes at a glance
18.9 mo
Median progression-free survival (FLAURA trial)
38.6 mo
Median overall survival, 1st-line metastatic
83%
Objective response rate in EGFR-positive patients
80%
Reduction in disease recurrence risk (adjuvant, ADAURA)
- Am I a candidate? — Take Decesion
1
Confirm EGFR mutation status
Requires tissue or liquid biopsy showing exon 19 deletion or L858R mutation before starting first-line treatment.
2
Identify your treatment stage
Used after surgical resection (adjuvant), as first-line therapy for metastatic disease, or after prior EGFR TKI progression with T790M mutation.
3
Review contraindications with your oncologist
Pregnancy, severe QTc prolongation, significant cardiac history — discuss fully before prescribing.
4
Discuss your goals of care
Weigh OS benefit against side-effect profile, dosing convenience (once daily oral), and your overall health status.
Important safety information: Osimertinib can cause serious lung problems (interstitial lung disease), heart rhythm changes (QTc prolongation), and is harmful to a developing baby. Do not take without confirmed EGFR mutation testing and close physician monitoring.
- common side effects to know
- Diarrhea (46%)
- Rash / dry skin (41%)
- Paronychia (nail) (25%)
- Fatigue (22%)
- ILD / pneumonitis (3.5%)
- QTc prolongation (1–3%)
- Trust & expertise
- FDA Approved 2015
- EMA Approved 2016
- NCCN Category 1
- FLAURA / ADAURA RCTs
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
“Osimertinib has transformed outcomes for EGFR-positive NSCLC. The CNS penetration and T790M efficacy make it the preferred option in most guidelines. Patient selection through proper biomarker testing is essential.”
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
Ready to discuss Tagrisso with your care team?
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Questions to ask my healthcare provider
What questions should I ask my oncologist about starting osimertinib?
Here are the most important questions to bring to your oncologist, organized by what stage of the conversation you’re in:
Before confirming osimertinib as your treatment
- Has my EGFR mutation been confirmed by biopsy — and which specific mutation do I have (exon 19 deletion, L858R, or T790M)?
- Is osimertinib being recommended as my first-line treatment, or because my previous EGFR therapy stopped working?
- Are there other options I should consider, and why is osimertinib the preferred choice for my case?
About what to expect on treatment
- What does “once daily oral” dosing look like in practice — does it matter when I take it, or with food?
- How will we know if it’s working, and how soon? What scans or tests will we do, and how often?
- Which side effects are most likely for me specifically, given my overall health?
- What symptoms should prompt me to call immediately versus wait for my next appointment?
About your specific situation
- Does my cancer have brain metastases, and does that change anything about this choice? (Osimertinib has strong CNS penetration — worth discussing explicitly.)
- If I’m considering having children, how does this affect that? For how long after stopping treatment?
- How does osimertinib interact with my other medications or supplements?
About the longer road
- What typically happens when osimertinib eventually stops working — do we retest for new mutations at that point?
- Is there a clinical trial I should know about alongside or after this treatment?
- Are there patient assistance programs if the cost is a concern? (Tagrisso has an AstraZeneca access program worth asking about.)
A practical tip: bring someone with you to the appointment to take notes, and ask your oncologist if you can record the conversation. These are complex answers and it helps to review them afterward.
compare with other therapies
Compare osimertinib vs other EGFR TKIs like erlotinib and gefitinib
Generation classification
Erlotinib and gefitinib are first-generation EGFR TKIs — they reversibly bind the EGFR receptor. Osimertinib is third-generation, designed specifically to target both common activating mutations and the T790M resistance mutation that often develops after first-generation drugs stop working.
Head-to-head: efficacy
| Gefitinib / Erlotinib (1st-gen) | Osimertinib (3rd-gen) | |
|---|---|---|
| Median PFS (first-line) | ~10–11 months | 18.9 months (FLAURA) |
| Median OS (first-line) | ~24–28 months | 38.6 months (FLAURA) |
| CNS (brain) penetration | Limited | Significantly better |
| Resistance mechanism addressed | None for T790M | Effective against T790M |
The FLAURA trial directly compared osimertinib to erlotinib/gefitinib as first-line treatment, and the survival difference (more than 10 months) was a major reason osimertinib became the preferred first-line standard in most guidelines (NCCN, ESMO).
Why osimertinib pulled ahead
About 50–60% of patients on first-generation TKIs eventually develop the T790M resistance mutation, at which point the drug stops working and a new biopsy is needed to confirm T790M before switching to osimertinib. Osimertinib was originally developed for this T790M-resistant population — but FLAURA showed it works even better when used first, partly because it delays or prevents that resistance pathway altogether, and partly because of its superior brain penetration (lung cancer frequently spreads to the brain).
Side effect profile differences
| 1st-gen (Gefitinib/Erlotinib) | Osimertinib | |
|---|---|---|
| Skin rash/acne | More frequent, often more severe | Present but generally milder |
| Diarrhea | Common | Common |
| Liver enzyme elevation | More frequent | Less frequent |
| Cardiac (QTc prolongation) | Rare | More notable — requires monitoring |
| Interstitial lung disease (ILD) | Rare | Slightly higher risk (~3.5%) |
Osimertinib is often described as better tolerated overall, particularly for skin and GI side effects, which matters a great deal for long-term quality of life on a daily medication.
Cost consideration
This is one area where first-generation drugs still have a role: gefitinib and erlotinib have generic versions available in many countries, making them substantially cheaper than osimertinib, which remains under patent in most markets. In some healthcare systems with limited access or cost constraints, a first-generation TKI followed by osimertinib upon T790M-confirmed progression remains a clinically valid sequencing strategy — though it requires an additional biopsy at progression.
Bottom line
For most newly diagnosed EGFR-positive patients with access to osimertinib, current guidelines favor it first-line due to superior survival, brain protection, and tolerability. The first-generation drugs remain relevant primarily where cost or access is a limiting factor, with osimertinib reserved for T790M-positive progression.
This is a meaningful decision that depends on your specific mutation, disease stage, and access situation — definitely one to walk through with your oncologist using your own pathology results.
Bottom line
For most newly diagnosed EGFR-positive patients with access to osimertinib, current guidelines favor it first-line due to superior survival, brain protection, and tolerability. The first-generation drugs remain relevant primarily where cost or access is a limiting factor, with osimertinib reserved for T790M-positive progression.
This is a meaningful decision that depends on your specific mutation, disease stage, and access situation — definitely one to walk through with your oncologist using your own pathology results.
How does testing work
How does EGFR mutation testing work for lung cancer?
EGFR mutation testing is the essential first step before any targeted therapy decision. Here’s how it works:
What’s being tested
EGFR (Epidermal Growth Factor Receptor) is a protein that, when its gene is mutated, causes cancer cells to grow uncontrollably. Testing identifies which specific mutation you have — because the mutation type determines which drug works best and at what stage.
The most clinically important mutations are exon 19 deletions and the L858R point mutation (both respond well to osimertinib first-line), and the T790M resistance mutation (which develops after earlier EGFR therapy, and is also osimertinib’s target).
The two sample sources
Tissue biopsy is the gold standard. A sample of tumour tissue is taken — either surgically or via bronchoscopy/CT-guided needle — and sent to a pathology lab. It gives the most complete picture but requires an invasive procedure.
Liquid biopsy (blood test) analyzes circulating tumour DNA (ctDNA) shed by cancer cells into the bloodstream. It’s less invasive and faster, and is particularly useful when a tissue sample is difficult to obtain or when monitoring for acquired resistance mutations like T790M after treatment.
How the lab analyzes it
The lab uses one or more of these techniques:
- PCR-based assays — highly sensitive, fast, targets known mutations specifically
- Next-generation sequencing (NGS) — reads a broad panel of genes at once; preferred when comprehensive mutation profiling is needed
- FISH or IHC — used less often for EGFR specifically, more common for other lung cancer markers
NGS is increasingly the standard because it detects EGFR mutations and co-mutations (like TP53, MET amplification) that may affect prognosis or treatment sequencing.
Timeline
Tissue biopsy results typically take 1–2 weeks. Liquid biopsy can return results in 3–5 business days. In urgent situations, liquid biopsy may be used first while awaiting tissue confirmation.
What the result means for treatment
| Result | What it means |
|---|---|
| Exon 19 del or L858R | Osimertinib first-line is strongly indicated |
| T790M positive (after prior TKI) | Osimertinib second-line is indicated |
| EGFR negative | Other pathways tested (ALK, ROS1, PD-L1, etc.) |
| Uncommon EGFR mutations (exon 20 ins, etc.) | Different drugs may apply; discuss with oncologist |
One important nuance
EGFR testing isn’t done once and forgotten. If your cancer progresses on osimertinib, re-biopsy and re-testing is standard — resistance mechanisms evolve, and new mutations guide what comes next (MET amplification, C797S, HER2, small-cell transformation are all possibilities).
Would you like to understand any specific part of this more deeply — such as what to expect during a biopsy, or how to read your pathology report?
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
